HOLOGIC INC. overview

Hologic, Inc. (Nasdaq: HOLX) announced today that Wayde McMillan has been elected to the Company’s Board of Directors, effective April 4, 2025. Mr. McMillan was also appointed to the Audit and Finance Committee effective April 4, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250404530519/en/ Mr. McMillan has served as the Chief Financial Officer of Solventum Corporation, a carve-out health care company of 3M Company, since...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2025 on Thursday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 6553890. Participants...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Raymond James & Associates' 46th Annual Institutional Investors Conference on Tuesday, March 4 at 11 a.m. Eastern Time (ET). The presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com . The webcast will be available for 30 days following each event. About Hologic Hologic, Inc. is an innovative medical technology company...

Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today announced that its Affirm ® Contrast Biopsy Software, which combines contrast-enhanced diagnostic capabilities with accurate lesion targeting to help streamline workflow and accelerate biopsy procedures, 1-2 is now CE-marked. The technology received clearance from the U.S. Food and Drug Administration in October 2020. Designed from the ground up to integrate with the Selenia ® Dimensions ® and 3Dimensions™ systems,...

Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Aptima® SARS-CoV-2 assay, which was first granted Emergency Use Authorization (EUA) status in May 2020. “Our COVID test was instrumental in addressing critical testing needs during the pandemic and offered healthcare providers and laboratories a solution that was highly sensitive and able to help mitigate outbreaks. Nearly five years after the...

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 28, 2024 . “Our financial results for the first quarter of 2025 were consistent with our guidance overall,” said Stephen P. MacMillan, the Company’s Chairman, President and Chief Executive Officer. “Total revenue finished in line with our guidance on a constant currency basis, and improved profitability helped us post non-GAAP earnings per share at the high end of...

Minicarm.com: Your Go-To Source for Hologic Fluoroscan Mini C-Arm Sales, Parts & Service HAUPPAUGE, NEW YORK / ACCESS Newswire / February 4, 2025 / Hologic has officially announced the End-of-Sale and End-of-Life for the Hologic Fluoroscan InSight FD Mini C-Arm , with sales discontinuing on September 30, 2025. While Hologic has stated they will provide limited service and parts support for up to seven years after installation, units installed in 2018 or earlier will no longer be guaranteed...

Women’s cancer testing has declined globally, according to the latest Hologic Global Women’s Health Index , one of the largest collections of data on women’s health and well-being. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121461870/en/ Hologic, Inc. (Nasdaq: HOLX), a leading women’s health innovator, partners with Gallup to create the Index. Now in its fourth year, the Index raises new concerns about declining trends...